MAPK- driven glioma progression and reprogramming of the tumor-associated immune response
Ontology highlight
ABSTRACT: Glioma evolution is associated with disease progression and therapeutic resistance. We recently identified a group of MAPK-driven glioma with CDKN2A homozygous deletion that are low-grade and immune enriched. However, Over time, these tumors can progress to aggressive, higher-grade tumors. While low-grade tumors may be amenable to immunotherapeutic strategies, it is unknown how the tumor and its microenvironment evolve.
ORGANISM(S): Homo sapiens
PROVIDER: GSE312124 | GEO | 2026/07/16
REPOSITORIES: GEO
ACCESS DATA